Posted on 12/01/2010 in Pharmaceutical Company Product News Sanofi Pasteur has signed a contract with the privately held biotech company KaloBios Pharmaceuticals, which will see the two collaborate to develop an antibody to treat and prevent Pseudomonas aeruginosa (Pa) infections.
As part of the agreement, Sanofi Pasteur will hold the worldwide rights to KaloBios technology for all disease indications related to Pa infections, with the expectation of cystic fibrosis and bronchiectasis.
The most severe Pa infections affect critically ill or hospitalised patients, attacking their respiratory systems and resisting many antibiotics.
Wayne Pisano, president and chief executive officer of Sanofi Pasteur, commented: "Hospital-acquired Pa infections are associated with very high levels of morbidity, mortality and costs and treating them represents a significant, unmet medical need."
Meanwhile, Sanofi Pasteur announced last week that its new influenza vaccine - which is set to be marketed under the name Fluzone - has been approved by the Food and Drug Administration. Other news stories from 12/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
